With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.13040-77-2,6-Chloro-2,2′-bipyridine,as a common compound, the synthetic route is as follows.
The reaction was performed under argon. Substituted azole (excess) and potassium tert-butoxide were dissolved at RT in dry and degassed DMSO. An exothermic reaction occurred. The mixture was stirred for 10 min to allow the reaction to finish and cool. Then, a substituted halopyridine was added. The reaction mixture was stirred for 24 h at 140C to give a suspension. It was cooled to RT. Water (50mL) was added: the product precipitated on stirring/sonication. The solid was filtered, washed with water, and extracted with dichloromethane and water. The organic layer was washed with water to extract DMSO. Purification by chromatography on silica (20g) removed the starting materials and by-products on elution with 0-0.4% CH3OH in CH2Cl2, and provided the pure product on elution with 0.4-1.0% CH3OH in CH2Cl2. Anal. Calc. for C15H14N4 (MW 250.30): C, 71.98; H, 5.64; N, 22.38. Found: C, 72.04; H, 5.48; N, 22.48%.
13040-77-2, 13040-77-2 6-Chloro-2,2′-bipyridine 11116850, acatalyst-ligand compound, is more and more widely used in various fields.
Reference£º
Article; Shavaleev, Nail M.; Kessler, Florian; Graetzel, Michael; Nazeeruddin, Mohammad K.; Inorganica Chimica Acta; vol. 407; (2013); p. 261 – 268;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI